Mirus Bio Introduces the NEW Quality Tested TransIT-VirusGEN® SELECT Transfection Reagent Designed for the Drug Discovery Pipeline in Gene and Cell Manufacturing
Madison, Wis. (July 25, 2019) ‒ The TransIT-VirusGEN® SELECT Transfection Reagent is developed for large-scale virus production for preclinical and early phase clinical trials and is identical in formulation to the fully synthetic and animal-origin-free, research-grade TransIT-VirusGEN® Transfection Reagent. TransIT-VirusGEN® SELECT is differentiated from the research-grade reagent by additional quality release testing that simplifies the process of qualifying ancillary materials used in the manufacture of viral vectors for preclinical and early phase clinical trials. Biopharmaceutical manufacturers can also expect:
- Performance – Efficient DNA delivery for large-scale production of high-titer viral vectors
- Quality – Tested to confirm performance, formulation identity, sterility, low endotoxin levels, and absence of mycoplasma
- Reliability – Exceptional lot-to-lot consistency
- Flexibility – Compatible with multiple virus production platforms
“When we released TransIT-VirusGEN® for the research market over a year ago, we knew maximizing recombinant lentivirus and AAV titers was needed to support large scale manufacture of the vectors,” said Laura Juckem, Ph.D., Vice President of Scientific Operations. “Now with the additional quality testing, we can offer a superior ancillary material for the drug discovery pipeline, further supporting the use TransIT-VirusGEN® reagents in early clinical studies.”
“All TransIT-VirusGEN® reagents are designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV),” said Josh Snow, Ph.D., Director of Business Development & Marketing Strategy. “TransIT-VirusGEN® SELECT outperforms PEI and PEIpro® reagents and offers a simplified, cost-effective workflow, making it the clear choice for large-scale virus production in applications such as CAR-T cell therapy.”
“Gene and cell therapies are finally coming of age, and there has never been more demand to move research breakthroughs into the clinic,” added Snow. “Responding to the changing needs of the scientific community has always been a priority and a strength at Mirus. Our TransIT-VirusGEN® SELECT product enables a smooth transition from discovery through preclinical and early clinical manufacturing. Mirus will take the next step of introducing a Good Manufacturing Practice (GMP) reagent to the market in 2020 to support the entire gene therapy manufacturing process.”
Interested researchers can visit www.mirusbio.com/SELECT for comprehensive information about the TransIT-VirusGEN® SELECT Transfection Reagent and to request a free sample.
CONTACT:
Laura Juckem, Ph.D.
Vice President, Scientific Operations
Mirus Bio LLC
Ph: 608.441.2852
Fax: 608.441.2849
Email: laura.juckem@mirusbio.com
Josh Snow, Ph.D.
Director of Business Development & Marketing Strategy
Mirus Bio LLC
Ph: 608.441.2852
Fax: 608.441.2849
Email: josh.snow@mirusbio.com
THE TRANSFECTION EXPERTS – Mirus Bio pioneered scientific breakthroughs in non-viral gene delivery and continues to produce industry-leading transfection reagents. As we expand our expertise in nucleic acid delivery, we give life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing and genome editing.